Q BioMed Inc. Finalizes License Agreement With Oklahoma Medical Research Foundation and the Rajiv Gandhi Centre for Biotechnology for Novel Liver Cancer Treatment

NEW YORK, June 15, 2017 /PRNewswire/ — Q BioMed Inc. (QBIO), is very pleased to announce their entry into a final license agreement with The Oklahoma Medical Research Foundation (OMRF) and the Rajiv Gandhi Centre for Biotechnology (RGCB). Under the agreement QBioMed has the global exclusive rights to develop and market a novel chemotherapeutic drug […]

Read More

Q BioMed Announces Attendance at Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

COMPANY EXECUTIVES AND TECHNOLOGY PARTNERS TO ATTEND INDUSTRY GATHERING JUNE 10-14 2017   NEW YORK, June 9, 2017 — Q BioMed Inc. (OTCQB: QBIO), and executives from its advanced technology partner Bio-Nucleonics Inc. will attend the upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting that is being held in Denver, Colorado June […]

Read More

Q BIOMED INC ANNOUNCES TWO NEW MEMBERS TO ITS SCIENTIFIC ADVISORY BOARD

COMPANY ADDS HIGHLY EXPERIENCED INDUSTRY ADVISORS TO ITS STRATEGIC RESOURCE TEAM   NEW YORK, April 13, 2017 —  Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company is pleased to announce the appointment of Dr. Amy Ripka and Dr. Rick Panicucci to its board of scientific advisors.     Dr. Amy Ripka is Executive Director […]

Read More

Q BioMed Announces 2nd Closing on Funding and Advances Cancer Palliation Drug

COMPANY GEARS UP FOR PRODUCTION OF CANCER PAIN PALLIATION DRUG WITH COMMERCIAL LAUNCH EXPECTED IN Q2 2017   NEW YORK, March 22, 2017 — Q BioMed Inc. (OTCQB: QBIO), has closed on its 2nd tranche of the $4,000,000 funding announced on November 30th 2016. The company received $1,000,000 on the 2nd closing bringing the total […]

Read More

Q BIOMED JOINS WITH OKLAHOMA MEDICAL RESEARCH FOUNDATION AND RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY TO DEVELOP LIVER CANCER CHEMOTHERAPEUTIC

NEW YORK, February 7, 2017 – Q BioMed, Inc. (OTCQB: QBIO) has entered into an agreement with the Oklahoma Medical Research Foundation (OMRF) and the Rajiv Gandhi Centre for Biotechnology (RGCB) to develop a chemotherapeutic technology to treat liver cancer.   The technology will utilize “uttroside B” and the compound’s derivatives as a chemotherapeutic agent […]

Read More
Social media & sharing icons powered by UltimatelySocial